For this purpose, the present study has been designed to assess the clinical efficacy of resveratrol as a monotherapy on serum level of both type II collagen (Coll 2-1) “a biomarker of collagen network degradation” and aggrecan “a degradation product of articular cartilage” biomarkers and on the evaluation of pain and OA symptoms in patients with mild and moderate knee osteoarthritis before and after 90-day administration of oral doses of resveratrol. Here, ACAN is linked to osteoarthritis, knee.